glp-1 receptor agonists should be avoided in patients with Safety and Tolerability of Glucagon-Like Peptide-1 Agonists: A State-of-the-Art Narrative Review | Drugs How GLP-1 Receptor Agonists Evolved

In January 2025, the firm published results of a Phase 2 trial for VK2735 with strong potential, including up to nearly 15% of baseline body weight lost in trial participants without a clear plateau

Corbin KD, Carnero EA, Allerton TD, Tillner J, Bock CP, Luyet PP, et al

Any prescribing decision belongs with a clinician who can assess the individual patient's age, weight, comorbidities, and development stage

These innovations aim to offer more potent and durable clinical outcomes, improve patient responsiveness and address the growing need for advanced therapies within the global obesity landscape

Gently swirl the vial with a circular wrist motion

Importantly, many of the earlier concerns were derived from animal models or spontaneous adverse event reporting systems, which are limited by their observational nature and lack of control groups (Davies et al., 2021